Skip to content
PICO Portalanswers from OpenAlex

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

PaperCitations, authors & open-access status

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis is a paper indexed in PICO Portal from OpenAlex.

How many citations does Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis have?

PICO Portalcitation count

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis has 944 citations in the OpenAlex counts PICO Portal stores.

When was Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis published?

PICO Portalyear

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis has 2012 year in the PICO Portal index.

What is the open-access status of Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis?

PICO Portaloa status

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis has bronze oa status in the PICO Portal index.

What is the DOI of Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis?

PICO Portaldoi

The DOI for Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis is on the source record.

What is the PMID of Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis?

PICO Portalpmid

The PMID for Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis is on the source record.

What is the OpenAlex record for Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis?

PICO Portalopenalex

The OpenAlex for Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial